Evidence map›Paper›PMID 42504646›Full record

ArticleImmunity, inflammation and disease2026

Takayasu Arteritis and Giant Cell Arteritis: Results From a Cross-Sectional Study of 96 Italian Patients.

Marcella Prete, Nicola Susca, Elvira Favoino, Federico Perosa, Daniele Tragni, Luca Navarini, Irene Genovali, Piero Ruscitti, Paola Cipriani, Pasquale Pignataro and 4 more

Abstract readMulticenter Study
In one paragraph

Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marcella PreteInternal Medicine Unit, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
Nicola SuscaInternal Medicine Division, Santa Chiara Hospital, Provincial Health Care Agency (APSS), Trento, Italy.
Elvira FavoinoRheumatic and Systemic Autoimmune Diseases Unit, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.ORCID https://orcid.org/0000-0002-4664-1394
Federico PerosaRheumatic and Systemic Autoimmune Diseases Unit, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
Daniele TragniInternal Medicine Unit, Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
Luca NavariniClinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Bio-Medico, Rome, Italy.
Irene GenovaliRheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, University of Rome "Campus Biomedico" School of Medicine, Rome, Italy.
Piero RuscittiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Aquila, Italy.
Paola CiprianiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Aquila, Italy.
Pasquale PignataroSection of Radiology and Radiation Oncology, Azienda Ospedaliero-Universitaria Policlinico di Bari, Bari, Italy.
Anna CirulliInternal Medicine Unit, Azienda Ospedaliero-Universitaria Policlinico di Bari, Bari, Italy.
Antonio MazzoccaDepartment of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
Patrizia LeoneDepartment of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
Vito RacanelliCentre for Medical Sciences, Santa Chiara Hospital, Provincial Health Care Agency (APSS), University of Trento and Internal Medicine Division, Trento, Italy.ORCID https://orcid.org/0000-0002-8639-1940

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large-vessel vasculitis (LVV), are distinct clinical entities or different manifestations of the same disease is an ongoing debate. This study analyzes and compares the clinical manifestations, imaging characteristics, and diagnostic and therapeutic features of TAK and GCA in a longitudinal cohort of patients recruited from three Italian centers.

methodsThe study population consisted of 59 patients with TAK and 37 with GCA, including 7 with cranial-GCA (C-GCA) and 30 with large vessel-GCA (LV-GCA), all diagnosed between January 2014 and November 2025. Most (72%) were followed up for at least 60 months.

resultsIn TAK patients, the time to diagnosis following the onset of symptoms was longer (p = 0.025), the prevalence of females higher (p = 0.001), and the presence at diagnosis of constitutional symptoms (p < 0.001), cardiovascular signs (p < 0.001), renal (p = 0.006) and dermatologic involvement (p = 0.040) more frequent than in GCA patients. In GCA patients, the sex distribution was equal. However, in addition to the cranial and constitutional symptoms associated with the cranial and large vessel forms of the disease, respectively, the prevalence of polymyalgia rheumatica (p < 0.001), hypertension (p < 0.001), diabetes mellitus (p = 0.003), and chronic liver disease (p = 0.02) was higher in GCA than in TAK patients. Vascular involvement was observed in both groups, with participation of the axillary artery more frequent in GCA patients (p = 0.02). Additionally, involvement of the aortic arch (p = 0.009), mesenteric (p = 0.004), and renal (p < 0.001) arteries was more frequent in TAK patients. Glucocorticoids were administered at a higher dose (p < 0.001) and combined more frequently with immunosuppressants in TAK patients. Among relapsing/refractory GCA patients, 50% received tocilizumab as second-line treatment. The two groups did not significantly differ concerning long-term remission, but relapse was more frequent in TAK patients.

conclusionsDespite their phenotypic similarities, TAK and GCA differ in their epidemiological and genetic features and, to a lesser extent, in their clinical manifestations, arterial involvement, and response to therapy. Our data therefore indicate that TAK and GCA are clinically distinct, requiring disease-specific approaches in their diagnosis and management.

Indexed as

Giant Cell ArteritisTakayasu ArteritisAdultAgedAged, 80 and overCross-Sectional StudiesFemaleHumansItalyMaleMiddle Ageddisease activitygiant cell arteritislarge vessels vasculitismedical treatmentTakayasu arteritis

Identifiers

PMID42504646
PMCPMC13403052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.